Elite 50% OFF Act now – get top investing tools

00

Days

00

Hours

00

Mins

00

Sec

Register Now!

Daré Bioscience, Inc.

Contributing Author

Recent Articles by Daré Bioscience, Inc.

11 hours	Dare Bioscience Announces Return of Rights to Ovaprene; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization DARE -9.24% GlobeNewswire
Nov-24	Dare Bioscience Receives $3.6 Million in Additional Grant Funding DARE GlobeNewswire
Nov-13	Dare Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update DARE GlobeNewswire
Nov-11	Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream; November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health DARE GlobeNewswire
Nov-06	Dare Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 DARE GlobeNewswire
Nov-03	Dare Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment DARE GlobeNewswire
Oct-06	Dare Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders DARE GlobeNewswire
Sep-24	Dare Bioscience to Receive up to $499,000 to Support Preeclampsia Research DARE GlobeNewswire
Aug-14	Dare Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update DARE GlobeNewswire
Aug-07	Dare Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025 DARE GlobeNewswire
Jul-29	Dare Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY Sildenafil Cream DARE GlobeNewswire
Jul-21	UPDATE - Dare Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar DARE GlobeNewswire
Jul-21	Dare Bioscience to Host August 6 Webinar: The DARE to PLAY Difference - The Sildenafil Cream That Raises the Bar DARE GlobeNewswire
Jul-14	Positive Interim Phase 3 Results Highlight Potential of Ovaprene, Novel Hormone-Free Contraceptive DARE GlobeNewswire
Jul-11	Dare Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders DARE GlobeNewswire
Jun-12	Dare Bioscience Announces Adjournment of Annual Meeting of Stockholders DARE GlobeNewswire
Jun-04	Dare Bioscience and Rosy Wellness Announce Strategic Collaboration to Educate and Market Dare's DARE to PLAY Sildenafil Cream DARE GlobeNewswire
May-13	Dare Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update DARE GlobeNewswire
May-06	Dare Bioscience to Host First Quarter 2025 Financial Results and Company Update Conference Call and Webcast on May 13, 2025 DARE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 Finviz.com. All Rights Reserved.